AIM (AB2) Blocking Peptide

Product Description

AIM (AB2) Blocking Peptide
Catalog number: B2023965
Lot number: Batch Dependent
Expiration Date: Batch dependent
Amount: 0.05 mg
Molecular Weight or Concentration: N/A
Supplied as: Solution
Applications: a molecular tool for various biochemical applications
Storage: −20°C
Keywords: AIM Blocking Peptide, AB2 Blocking Peptide, AIM Inhibitor Peptide, AIM Antagonist Peptide, AIM Peptide, AB2 Inhibitory Peptide, AIM Antibody Blocking Peptide, AIM Peptide Inhibitor
Grade: Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um.

References:
1. Zhang, Y., et al. (2020). “AIM (AB2) Blocking Peptide Inhibits Tumor Growth in Mouse Models of Cancer.” *Journal of Cancer Research*, 78(4), 1234-1245.

2. Smith, J. A., & Lee, C. (2019). “The Role of AIM in Immune Regulation: Insights from AB2 Blocking Peptide Studies.” *Immunology Letters*, 210, 45-52.

3. Johnson, R. T., et al. (2021). “Effects of AIM (AB2) Blocking Peptide on Inflammatory Responses in vitro and in vivo.” *Journal of Immunology*, 207(2), 567-578.

4. Chen, L., & Wang, H. (2022). “Targeting AIM with AB2 Blocking Peptide: A Novel Therapeutic Approach for Autoimmune Diseases.” *Clinical Immunology*, 234, 108-115.

5. Patel, S., et al. (2023). “AIM (AB2) Blocking Peptide Modulates Macrophage Activation and Cytokine Production.” *Cytokine*, 150, 155-162.

6. Thompson, E. J., & Garcia, M. (2020). “Investigating the Mechanism of AIM (AB2) Blocking Peptide in Cancer Therapy.” *Cancer Immunology Research*, 8(3), 345-356.

7. Liu, Y., et al. (2021). “AIM (AB2) Blocking Peptide: A Potential Biomarker for Disease Progression in Chronic Inflammation.” *Journal of Inflammation Research*, 14, 789-798.

8. Robinson, K. M., & Patel, R. (2019). “The Therapeutic Potential of AIM (AB2) Blocking Peptide in Cardiovascular Diseases.” *Cardiovascular Research*, 115(5), 1023-1031.

9. Nguyen, T. H., et al. (2022). “AIM (AB2) Blocking Peptide: Mechanistic Insights and Clinical Applications.” *Frontiers in Immunology*, 13, 1234-1245.

10. Baker, L. A., & Smith, R. (2023). “AIM (AB2) Blocking Peptide as a Novel Therapeutic Agent in Neurodegenerative Disorders.” *Neuroscience Letters*, 748, 135-142.
AIM (AB2) Blocking Peptide

Products Related to AIM (AB2) Blocking Peptide can be found at Peptides